For CLL, this suggests that transient IL‐10 blockade may counteract tumor‐driven suppression, while preserving long‐term IL‐10R signaling required to maintain progenitor‐like CD8+ T cells. The gene discussed is IL10RA; the disease is B-cell chronic lymphocytic leukemia.